ACADIA Pharmaceuticals (NASDAQ:ACAD), a biopharmaceutical company, recently announced their third quarter financial results on November 6, after the market close. The company announced the attainment of various clinical milestones, over the quarter. The share prices of ACADIA dipped almost 7% before the earnings release due to the rumors, which were proved correct, that the losses of the firm will widen in the third quarter.
ACADIA saw a substantial up-rise in its stock prices since the beginning of 2013. This was attributed to the positive clinical trial results of Pimavanserin, a potential treatment for Parkinson's disease psychosis (NASDAQ:PDP). The FDA in April agreed to cancel the phase III-021 confirmatory trial for Pimavanserin, owing to the positive results...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|